Seeking Alpha

Aeterna Zentaris (AEZS) lands IND FDA approval for the initiation of a Phase 2A trial to assess...

Aeterna Zentaris (AEZS) lands IND FDA approval for the initiation of a Phase 2A trial to assess the firm's treatment for cancer cachexia. The firm says if its AEZS-130 drug is effective, subjects could receive more effective doses of chemotherapy and have a better functional status.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs